Dr. Reddy’s shares fall after it gets USFDA letter

Launch of 2 products may be affected

August 14, 2019 11:01 pm | Updated 11:01 pm IST - HYDERABAD

Dr. Reddy’s Laboratories stock fell 8% intraday on Wednesday on the back of an update from the company about the US Food and Drug Administration (USFDA) communication that is likely to have a bearing on the early launch of two generic products.

“Received Complete Response Letter (CRL) from USFDA; Preparing for response,” is what the company had said in an investor update for August 2019 on the launch of the generic versions of Copaxone and NuvaRing.

According to USFDA, a CRL is issued to an applicant “if the agency determines that we will not approve the application or abbreviated application in its present form for one or more of the reasons...” Copaxone (glatiramer acetate injection) is indicated for relapsing forms of multiple sclerosis, NuvaRing is used to prevent pregnancy.

Meanwhile, the stock recovered some lost ground and closed at ₹2,511.20, 1.83% lower from the previous close. In response to a clarification sought by the exchange, Dr. Reddy’s mentioned the update provided the previous day to investors as well as referred to the earnings call on July 29 when it had pointed to possible queries from USFDA on NuvaRing.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.